- Data presented demonstrates improved
ex vivo PM21 expansion of NK cells when pre-activated with
cytokines.
Amsterdam, The Netherlands, May 28, 2020 – Kiadis Pharma
N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels:
KDS), a clinical stage biopharmaceutical company,
announces that new data related to its K-NK cell therapy platform
will be presented today at the International Society of Cell &
Gene Therapy (ISCT) virtual annual meeting. Poster #228, from the
lab of Alicja Copik, Ph.D., at the University of Central Florida,
will present data that shows how cytokine pre-activation enhances
Kiadis’ PM21-particle driven NK cell expansion.
Dr. Copik’s group performed preclinical research to understand
how both the expansion and the activity of ex vivo expanded NK
cells can be further enhanced by coupling the PM21 expansion
process with cytokine pre-activation prior to the expansion. This
results in high-scale expansion of NK cells with a “memory-like”
phenotype that can be re-activated upon detection of stimuli,
resulting in a more potent response upon tumor detection. Other
methods for producing NK cells with “memory-like” features have
been developed and applied clinically, but cell yields were low and
manufacturing processes were not amenable to scalable, commercial
development.
Results presented as part of Dr. Copik’s poster at ISCT
demonstrate that high-scale expansion of “memory-like” NK cells can
be obtained with a combined pre-activation with cytokines followed
by expansion with Kiadis’ PM21-platform. NK cells from healthy
donor-derived peripheral blood mononuclear cell (PBMCs) were
stimulated overnight with IL-12, IL-18 and IL-15 and then expanded
with PM21 particles. The new methodology resulted in a
significantly further increased expansion of NK cells than with
PM21 alone. Also, the NK cells that were preactivated produced even
larger amounts of IFNγ and were very responsive to activation by
K562 tumor cells or cytokines.
In addition, receptor expression was similar for both cytokine
preactivated NK and PM21 activated NK cells and demonstrated that
both are in a highly activated state as compared to IL-2 activated
NK cells. In vitro and in vivo data are also presented that confirm
their anti-leukemic effects.
In summary, pre-activation with IL-12, IL-18 and IL-15 followed
by PM21 particle expansion leads to significantly further increases
of NK cells. Such NK cells have further enhanced IFNγ production
upon stimulation with cytokines or tumor cells compared to PM21-NK
cells without pre-activation, to yield a unique NK cell phenotype
with a hyper-functional phenotype and potent therapeutic
potential.
Robert Friesen, Chief Scientific Officer of Kiadis, commented,
“The data presented today demonstrate the Kiadis platform can be
further improved upon and we are excited to potentially incorporate
this methodology into our manufacturing options to possibly attain
even higher yields of more potent therapeutic NK cells that would
further increase accessibility to patients in urgent need of novel
therapeutic options.”
The poster is available at www.kiadis.com.
Kiadis Contacts:
Kiadis:Maryann Cimino, Sr. Manager, Corporate
AffairsTel: +1 (617) 710-7305m.cimino@kiadis.com |
Optimum Strategic Communications:Mary Clark,
Supriya Mathur, Hollie VileTel: +44 203 950 9144David Brilleslijper
(Amsterdam)Tel: +31 610 942 514kiadis@optimumcomms.com |
Dutch Translation/Nederlandse vertaling
Kiadis Pharma N.V. (‘Kiadis’), een
biofarmaceutisch bedrijf gericht op onderzoek in de klinische fase,
zal nieuwe informatie over het K-NK-celtherapieplatform presenteren
op het jaarlijkse ISCT-congres (International Society of Cell &
Gene Therapy). Op poster #228 van het laboratorium van Alicja
Copik, Ph.D., werkzaam bij de University of Central Florida, zal
informatie worden gepresenteerd over hoe de cytokine-preactivering
de op PM21 gebaseerde NK-celexpansie van Kiadis verbetert.
De groep van Dr. Copik voerde preklinisch onderzoek uit om
inzicht te krijgen in hoe het PM21-expansieproces vóór expansie
gecombineerd kan worden met cytokine-preactivering om zowel de
expansie als de activiteit van ex vivo geëxpandeerde NK-cellen te
verbeteren. Dit resulteert in een grootschalige expansie van
NK-cellen met een uniek fenotype dat gereactiveerd kan worden bij
detectie van stimuli. Hierdoor is een krachtigere respons mogelijk
bij tumordetectie. Er werden al andere klinische methoden
ontwikkeld en toegepast om NK-cellen te produceren met
cytokine-preactivering, maar daarbij was de celopbrengst laag en
waren de productieprocessen niet geschikt voor schaalbare,
commerciële toepassingen.
De resultaten die op het ISCT-congres worden getoond op de
poster van Dr. Copik tonen aan dat een grootschalige expansie van
unieke NK-cellen mogelijk is door een combinatie van
cytokine-preactivering gevolgd door expansie met het PM21-platform
van Kiadis. NK-cellen afkomstig van perifere mononucleaire
bloedcellen (PBMC’s) van een gezonde donor werden kort gestimuleerd
met IL-12, IL-18 en IL-15 en vervolgens geëxpandeerd met
PM21-deeltjes. De nieuwe methodologie resulteerde in een
significant verder vergrote toename van NK-cellen dan wanneer
alleen PM21 werd toegepast. De NK-cellen die vooraf werden
geactiveerd, produceerden bovendien grote hoeveelheden IFNγ en
reageerden zeer goed op activering door K562-tumorcellen of
cytokines.
Daarnaast was de receptorexpressie van met cytokine
gepreactiveerde NK-cellen vergelijkbaar met PM21-geactiveerde
NK-cellen. Beide varianten bevinden zich in een zeer geactiveerde
toestand in vergelijking met IL-2-geactiveerde NK-cellen. Er worden
ook in-vitro- en in-vivogegevens getoond die de antileukemische
werking van de NK cellen bevestigen.
Kortom, preactivering met IL-12, IL-18 en IL-15 gevolgd door
PM21-expansie leidt tot een significant hogere expansie van
NK-cellen. De IFNγ-productie bij stimulatie met cytokines of
tumorcellen is bij dergelijke NK-cellen verder verbeterd dan
wanneer enkel PM21-deeltjes worden toegepast zonder preactivering.
Dit resulteert in een uniek, hyperfunctioneel fenotype voor
NK-cellen met een groot therapeutisch potentieel.
Robert Friesen, Chief Scientific Officer bij Kiadis, zei: “De
informatie die we vandaag hebben gepresenteerd toont aan dat het
Kiadis-platform nog verder kan worden verbeterd. We zijn verheugd
om deze methodologie mogelijk toe te passen in onze
productiemethoden. Dit kan in betere therapeutische NK-cellen met
een hogere opbrengst resulteren, waardoor we meer patiënten met een
dringende behoefte aan nieuwe therapeutische opties kunnen
helpen.”
De poster is beschikbaar op www.kiadis.com.
Dit persbericht vormt een vertaling van het
gepubliceerde Engelstalige persbericht. Bij eventuele verschillen
is de tekst van het Engelstalige persbericht altijd
bepalend.
About Kiadis’ K-NK-Cell Therapies Kiadis’
NK-cell programs consist of off-the-shelf and haplo donor cell
therapy products for the treatment of liquid and solid tumors as
adjunctive and stand-alone therapies.
The Company’s NK-cell PM21 particle technology enables improved
ex vivo expansion and activation of anti-cancer cytotoxic NK-cells
supporting multiple high-dose infusions. Kiadis’ proprietary
off-the-shelf NK-cell platform is based on NK-cells from unique
universal donors. The Kiadis off-the-shelf K-NK platform can make
NK-cell therapy product rapidly and economically available for a
broad patient population across a potentially wide range of
indications.
Kiadis is clinically developing K-NK003 for the treatment of
relapse/refractory acute myeloid leukemia. The Company is also
developing K-NK002, which is administered as an adjunctive
immunotherapeutic on top of HSCT and provides functional, mature
and potent NK-cells from a haploidentical family member. In
addition, the Company has pre-clinical programs evaluating NK-cell
therapy for the treatment of solid tumors.
About KiadisFounded in 1997, Kiadis is building
a fully integrated biopharmaceutical company committed to
developing innovative therapies for patients with life-threatening
diseases. With headquarters in Amsterdam, the Netherlands, and
offices and activities across the United States, Kiadis is
reimagining medicine by leveraging the natural strengths of
humanity and our collective immune system to source the best cells
for life.
Kiadis is listed on the regulated market of Euronext Amsterdam
and Euronext Brussels since July 2, 2015, under the symbol KDS.
Learn more at www.kiadis.com.
Forward Looking Statements Certain statements,
beliefs and opinions in this press release are forward-looking,
which reflect Kiadis’ or, as appropriate, Kiadis’ officers’ current
expectations and projections about future events. By their nature,
forward-looking statements involve a number of known and unknown
risks, uncertainties and assumptions that could cause actual
results, performance, achievements or events to differ materially
from those expressed, anticipated or implied by the forward-looking
statements. These risks, uncertainties and assumptions could
adversely affect the outcome and financial effects of the plans and
events described herein. A multitude of factors including, but not
limited to, changes in demand, regulation, competition and
technology, can cause actual events, performance, achievements or
results to differ significantly from any anticipated or implied
development. Forward-looking statements contained in this press
release regarding past trends or activities should not be taken as
a representation that such trends or activities will continue in
the future. As a result, Kiadis expressly disclaims any obligation
or undertaking to release any update or revisions to any
forward-looking statements in this press release as a result of any
change in expectations or projections, or any change in events,
conditions, assumptions or circumstances on which these
forward-looking statements are based. Neither Kiadis nor its
advisers or representatives nor any of its subsidiary undertakings
or any such person’s officers or employees guarantees that the
assumptions underlying such forward-looking statements are free
from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the anticipated or
implied developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.